Sunesis Pharmaceuticals, Inc. Company Profile

10:38 EST 18th November 2017 | BioPortfolio

News Articles [469 Associated News Articles listed on BioPortfolio]

Sunesis Pharmaceuticals (SNSS) - A new BTK for a new day

Edison Investment Research - Pharmaceutical & healthcare - Sunesis Pharmaceuticals: Sunesis remains on track to complete the dose-escalation portion of its Phase Ib/II clinical trial for lead compound...

Sunesis Pharmaceuticals (SNSS) - SNS-062 trial up and running

Edison Investment Research - Pharmaceutical & healthcare - Sunesis Pharmaceuticals: Sunesis announced on 18 July 2017 that the first patient had been dosed in its Phase Ib/II study of SNS-062 for the ...

Sunesis Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 15102017] Prices from USD $350

Sunesis Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sunesis Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliance...

Sunesis nets $19mm through public offerings of common and preferred shares

Sunesis Pharmaceuticals Inc. (oncology) will use the proceeds from a $19mm public sale of common and preferred shares to support ongoing development of SNS062, a BTK inhibitor entering Phase I for B-c...

Sunesis Pharmaceuticals: SNS-062 Could Be The Company's Salvation

Sunesis Pharmaceuticals: Overhang Cleared For This Oncology Turnaround Story

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies

Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic...

Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2017. Loss fr...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]


PubMed Articles [120 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Effects of exposure to pharmaceuticals (diclofenac and carbamazepine) spiked sediments in the midge, Chironomus riparius (Diptera, Chironomidae).

Human and veterinary pharmaceuticals and degradation products are continuously introduced into the environment. To date, there is a lack of information about the effects of pharmaceuticals in spiked t...

Clinical Trials [206 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1287 Associated Companies listed on BioPortfolio]

Sunesis Pharmaceuticals, Inc.

Leader Ventures

Carmot Therapeutics was founded by Drs. Hansen and Erlanson in 2008 with the goal of commercializing and further developing Chemotype Evolution. Carmot has licensed the technology and fragment librari...

Sunesis Pharmaceuticals

Our vision: Sunesis will change the standards of care for the treatment of cancer by discovering, developing and marketing unique therapeutics that give hope to cancer patients and improve their live...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

More Information about "Sunesis Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Sunesis Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Sunesis Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Sunesis Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sunesis Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Sunesis Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record